We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Romark and Chugai Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
News

Romark and Chugai Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Romark and Chugai Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
News

Romark and Chugai Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Romark and Chugai Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Romark Laboratories and Chugai Pharmaceutical Co. Ltd. have announced that the two companies have entered into an exclusive license agreement for the development and commercialization of nitazoxanide as a treatment of chronic hepatitis C in Japan.

Under the terms of the agreement, Chugai has paid an upfront payment to Romark, and will make additional payments based on the achievement of certain clinical and regulatory milestones. Romark will participate in profits from product sales in Japan through a supply agreement and royalties.

"Chugai is an excellent partner for us in Japan. They bring substantial expertise in the development and marketing of treatments for chronic hepatitis C exemplified by their experience with Pegasys® and Copegus®," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark Laboratories, and inventor of the thiazolides. "This agreement is an important step in accelerating the worldwide development and commercialization of nitazoxanide for treating this disease."
Advertisement